Polyethylene glycol interferon-α2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia

Haematologica

Volumn 89, Issue 7, 2004, Pages 870-871

  Cervantes, Francisco ^a   Camós, Mireia ^b   Boqué, Concha ^b   Besses, Carles ^c   Alcalá, Antonio ^d   Sureda, Anna ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Ara C; Chronic myeloid leukemia; PEG interferon; Treatment

Indexed keywords

CYTARABINE; HYDROXYUREA; MACROGOL; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROLOGICAL COMPLICATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RESPIRATORY DISTRESS; SKIN MANIFESTATION; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 3242805235     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortés J, et al. Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 2001;98:1708-13.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
4. Baccarani M, Rosti G, Trabacchi E, Bassi S, Amabile M, Testoni N, et al. Imatinib and pegylated-α2b interferon in early chronic phase Ph+ chronic myeloid leukemia: 12-months results of a prospective phase I/II study by the Italian Cooperative Study Group on CML Blood 2003;102 Suppl 1:183a [abstract].
5. th Meeting European Hematology Association: Florence; Italy [abstract 0582].
6. Garcia-Manero G, Talpaz M, Giles FJ, Cortés J, Faderl S, O'Brien S, et al. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-α-2b and low-dose cytosine arabinoside. Cancer 2003;97:3010-6.
7. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. Pegylated recombinant interferon α-2b vs recombinant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004;18:309-15.